Opexa Therapeutics Reports Positive Top-line Data in Phase I/II ...
Business Wire (press release) - San Francisco,CA,USA
The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in a Phase IIb trial. The Company holds the exclusive worldwide license ...
See all stories on this topic